article
Expert view: Preparing drug discovery for smart screening era
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
article
Expert view: High-throughput binding kinetic analysis – is it the new frontier in drug discovery?
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
article
Supporting the progression of phenotypic hits with bioactivity profiling
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
whitepaper
Tech note: Long term live cell imaging in a high-content system
How to perform successful long term live cell imaging in a high-content analysis system.
news
Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
news
Charles River Laboratories expands services for early discovery screening
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.
news
SB216763 shows preclinical efficacy in Rett syndrome
Researchers describe how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome...
news
ELRIG UK hosts inaugural Discovery Technologies event
ELRIG (European Laboratory Research & Innovation Group) has announced its first Discovery Technologies meeting, which will take place at Alderley Park, located near Macclesfield in Cheshire.
webinar
Transforming translational research: CANscriptTM – A better predictive model for oncology
27 April 2018 | By Mitra Biotech
In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
webinar
Using bioactivity profiling to support the progression of phenotypic hits
27 April 2018 | By Eurofins Pharma Discovery Services
In this webinar, we discussed a recent case study where a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells. This resulted in the identification of 7 representative hits which provided starting points for new drug discovery opportunities.
webinar
Biomarker endpoints for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
webinar
in vitro phenotypic assays for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.
news
The European Life Sciences Community meets at BASEL LIFE
Leading experts of the European Life Sciences Community are engaging under the name BASEL LIFE to establish a bridge between science and business.
